β¨ Medicines Act Notices
NEW ZEALAND GAZETTE
No. 4
Health
Medicines Act 1981
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Sodium chloride 4 mmol/mL in 20 mL | Injection, ampoule | McGaw Biomed Limited, Point Chevalier, Auckland | |
| Isosorbide mononitrate 60 mg | Tablet, film coated | Euderma Srl., Superstrada Rimini, Italy and Valpharma SA., Serravalle, Republica di San Marino | Imtrate |
| Cisatracurium besylate 2 mg/mL in 2.5 mL, 5 mL, 10 mL, 25 mL | Injection, ampoule | Wellcome Foundation Limited, Dartford, Kent, United Kingdom | Nimbex |
| Cisatracurium besylate 5 mg/mL in 30 mL | Injection, vial | Wellcome Foundation Limited, Dartford, Kent, United Kingdom | Nimbex |
| Reteplase 10U and diluent | Powder for injection, vial Diluent, pre-filled syringe | Boehringer Mannheim GmbH., Mannheim, Germany | Rapilysin 10 U |
| Fexofenadine hydrochloride 60 mg | Capsule | Marion Merrell Dow Inc., Kansas City, Missouri, United States of America | Telfast |
| Remifentanil hydrochloride equivalent to 1 mg, 2 mg, 5 mg remifentanil base | Powder for injection, vial | Pharmacia & Upjohn nv/sa., Puurs, Belgium | Ultiva |
Dated this 6th day of January 1997.
KAREN O. POUTASSI (Dr), Director-General of Health, pursuant to delegation given by the Minister of Health on the 18th day of January 1996.
god419
Consent to the Distribution of Changed Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Ibuprofen 100 mg/5 mL in 50 mL, 100 mL, 200 mL | Suspension, oral | Whitehall-Robins, Richmond, Virginia, United States of America and Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia | Act-3 |
| Alteplase (plasminogen activator) 10 mg, 20 mg, 50 mg and diluent | Injection, powder, glass vial; diluent, ampoule | Dr Karl Thomae GmbH., Biberach, Biberach an der Riss, Germany | Actilyse |
| Ipratropium bromide monohydrate 0.52 mg equivalent to 0.5 mg ipratropium bromide, salbutamol sulphate 3.01 mg equivalent to 2.5 mg salbutamol in 2.5 mL | Solution, inhaled | Boehringer Ingelheim Limited, Bracknell, Berkshire, England | Combivent Respules |
| Etoposide phosphate 113.6 mg equivalent to 100 mg etoposide | Injection, powder, glass vial | Bristol-Caribbean Inc., Mayaguez, Puerto Rico | Etopophos |
| Cetylpyridinium chloride 1.5 mg | Lozenge | Barratts Pharmaceuticals Pty Limited, Blacktown, New South Wales, Australia | Lemsip |
| Cisapride 5 mg, 10 mg | Tablets | Janssen Pharmaceutic nv., Beerse, Belgium | Prepulsid, Prepulsid Forte |
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1997, No 4
NZLII —
NZ Gazette 1997, No 4
β¨ LLM interpretation of page content
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare6 January 1997
Medicines Act 1981, New Medicines, Distribution Consent
- KAREN O. POUTASSI (Dr), Director-General of Health
π₯ Consent to the Distribution of Changed Medicines
π₯ Health & Social WelfareMedicines Act 1981, Changed Medicines, Distribution Consent